Dyne Therapeutics Submits BLA to FDA for Z-Rostudirsen in DMD, Seeks Priority Review
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics has submitted a Biologics License Application (BLA) to the FDA for z-rostudirsen, its lead candidate for Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping. The company is seeking accelerated approval based on positive DELIVER trial data and has requested Priority Review, which could shorten the FDA's review period. This follows earlier disclosures in March and May where Dyne outlined its BLA submission and launch timelines. The actual submission is a significant step towards potential commercialization, with a U.S. launch targeted for Q1 2027 if Priority Review is granted and approval is timely.
At the time of this announcement, DYN was trading at $17.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.